# A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

> **NCT00250042** · PHASE2 · COMPLETED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 6 (actual)

## Conditions studied

- Leukemia, Other
- Cancer

## Interventions

- **DRUG:** Gleevec and Arsenic Trioxide

## Key facts

- **NCT ID:** NCT00250042
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2005-04
- **Final completion:** 2006-03
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2011-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00250042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00250042, "A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00250042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*